SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Top Cited Papers
- 20 August 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (24), 2617-2622
- https://doi.org/10.1200/jco.2014.60.2219
Abstract
The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown. S0809 was designed to estimate 2-year survival (overall and after R0 or R1 resection), pattern of relapse, and toxicity in patients treated with this adjuvant regimen. Eligibility criteria included diagnosis of EHCC or GBCA after radical resection, stage pT2-4 or N+ or positive resection margins, M0, and performance status 0 to 1. Patients received four cycles of gemcitabine (1,000 mg/m2 intravenously on days 1 and 8) and capecitabine (1,500 mg/m2 per day on days 1 to 14) every 21 days followed by concurrent capecitabine (1,330 mg/m2 per day) and radiotherapy (45 Gy to regional lymphatics; 54 to 59.4 Gy to tumor bed). With 80 evaluable patients, results would be promising if 2-year survival 95% CI were > 45% and R0 and R1 survival estimates were ≥ 65% and 45%, respectively. A total of 79 eligible patients (R0, n = 54; R1, n = 25; EHCC, 68%; GBCA, 32%) were treated (86% completed). For all patients, 2-year survival was 65% (95% CI, 53% to 74%); it was 67% and 60% in R0 and R1 patients, respectively. Median overall survival was 35 months (R0, 34 months; R1, 35 months). Local, distant, and combined relapse occurred in 14, 24, and nine patients. Grade 3 and 4 adverse effects were observed in 52% and 11% of patients, respectively. The most common grade 3 to 4 adverse effects were neutropenia (44%), hand-foot syndrome (11%), diarrhea (8%), lymphopenia (8%), and leukopenia (6%). There was one death resulting from GI hemorrhage. This combination was well tolerated, has promising efficacy, and provides clinicians with a well-supported regimen. Our trial establishes the feasibility of conducting national adjuvant trials in EHCC and GBCA and provides baseline data for planning future phase III trials.This publication has 35 references indexed in Scilit:
- Surgical Treatment of 144 Cases of Hilar Cholangiocarcinoma Without Liver‐Related MortalityWorld Journal of Surgery, 2013
- Gemcitabine and Cisplatin Is a Highly Effective Combination Chemotherapy in Patients With Advanced Cancer of the GallbladderAmerican Journal of Clinical Oncology, 2003
- Results of Postoperative Radiotherapy for Resectable Hilar CholangiocarcinomaWorld Journal of Surgery, 2003
- Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus documentGut, 2002
- Role of postoperative radiotherapy in the management of extrahepatic bile duct cancerInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Improved survival in resected biliary malignanciesSurgery, 2002
- A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignanciesInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Gallbladder cancerSeminars in Surgical Oncology, 2000
- Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2000